Industry Insights & Trends
Scaling Humanized Immune System Mouse Models: Optimize Your CD34+ Engraftment with High Quality Cells
Table of Contents CD34+ Humanized Immune System Mice MNC Cell Quality Assessment: Flow Cytometry Data from CGT Global Cell Viability Cell Purity Cell Count Sources of CD34+ Cells: Comparison Table for Bone Marrow and Cord Blood Bulk Isolated CD34+ for Humanized Mice About CGT Global and Additional Resources Frequently Asked Questions List of Abbreviations The…
For More InformationTop PBMC Suppliers for 2026: Fresh, Cryopreserved, and GMP-Grade Options Compared
Introduction Peripheral Blood Mononuclear Cells (PBMCs) are foundational to immunology, oncology, and cell therapy research. Whether they are used for functional assays, vaccine development, or discovery-stage therapeutic studies, PBMC quality directly impacts data accuracy and reproducibility. In 2026, researchers expect more than just availability. They look for documented donor screening, consistent viability, and responsive support.…
For More InformationBest Leukopak Suppliers for Cell Therapy in 2026: Pricing, Quality, and Turnaround Compared
Introduction When it comes to sourcing leukopaks for cell therapy or research, product quality is only half the story. Procurement delays, unanswered inquiries, and limited visibility can stall entire workflows. In 2026, speed and communication matter just as much as purity and yield. To help researchers, process developers, and procurement teams choose confidently, we reviewed…
For More InformationScaling Cell & Gene Therapy Development: How CGT Global Supports Research, Clinical Trials, and Commercialization
By Joanna Wirkus, PhD From RUO to cGMP, CGT Global delivers quality, consistency, and regulatory readiness to help researchers advance therapies from discovery to patients. Executive Summary CGT Global accelerates cell and gene therapy development from discovery to commercialization. By providing rapid and reliable access to high-quality RUO and cGMP-certified materials and operating FDA- and CLIA-certified…
For More InformationAlzheimer’s & Neurodegenerative Disease: A Global Challenge
Written by CGT Global Cell & Gene Therapy Is Shifting the Paradigm Recent CGT innovations are upending traditional models and opening new paths to treat or even reverse Alzheimer’s progression: 1. AAV-Based Gene Therapy (LX1001) 2. CRISPR-Engineered Microglia 3. Behavior-Reprogramming Gene Therapy (UC San Diego) 4. Stem Cells & MSC Therapies 5. iPSC TriCulture Models…
For More InformationMesenchymal Stem Cell Derived Exosomes: Revolutionizing Future Medical Treatments
Why are scientists excited about Mesenchymal Stem Cell Exosomes? Mesenchymal stem cell (MSC) exosomes are on the brink of revolutionizing future treatments for chronic diseases and injuries. These microscopic biological messengers represent a vital mechanism of cellular communication, potentially offering a biomolecular reset for human physiological processes. The Unique Capabilities of Mesenchymal Stem Cells Mesenchymal…
For More InformationBehind the Scenes at CGT Global’s Laboratory: Life in the Lab with Bryan
By Joanna Wirkus, PhD CD34+ Cell Isolation Process Previously in our Meet the Scientific Team blog, we gained insight into the background of CGT Global’s Laboratory Operations Manager in Folsom, California — Bryan — and his inspiration for his work. Today, we go behind the scenes, or behind the bench, to see what a day…
For More InformationMeet CGT Global’s Scientific Team: Bryan Pulling – Laboratory Operations Manager
Written by Joanna Wirkus, PhD Every day at CGT Global, our experienced team collaborates to deliver high quality cells to scientists around the world. Success starts with the strength of our team and the dedication of the people who power it. In this edition of Meet the Scientific Team, we’re proud to spotlight Bryan Pulling…
For More InformationFast-Track Your Therapy Pipeline with CGT Global’s Clinical Capabilities
By: Joanna Wirkus Despite exponential progress in the field of biology, inherited and preventable diseases continue to burden billions of people worldwide. Bridging the gap between laboratory discoveries and transformative clinical therapies remains a significant challenge, , and an urgent opportunity. High-quality biospecimens are foundational to this effort, enabling the advancement of cell and gene…
For More InformationWhen Politics Blocks Progress: Funding Health Discoveries in Peril
Shifting Political Priorities Threaten the Bedrock of Health Science Investment By: Joanna Wirkus PhD July 2025 ** For scientists under pressure from shifting funding priorities, CGT Global has curated a FREE downloadable funding toolkit with resources to support your long-term funding acquisition strategy. Complete with a grant planning checklist, a curated list of 35+ funding…
For More Information